Palatin Technologies(PTN)
CRANBURY, NJBiotechnology
Focus: Palatin Technologies is a public-stage biotechnology company focused on small-molecule therapeutics across ophthalmology, cardiovascular, respiratory, nephrology, and immunology. The company operates with minimal commercial revenue and is primarily R&D-driven with a diversified pipeline.
Profile data last refreshed 15h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Palatin Technologies
AI assessmentNot HiringNo open roles listed right now. Follow Palatin Technologies to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Palatin Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$9M
Pipeline & Clinical Trials
Bremelanotide
Sexual Arousal DisorderClinical Trials (1)
NCT00425256Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Phase 2Help build intelligence for Palatin Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.